FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288060877> ?p ?o ?g. }

• W4288060877 endingPage "529" @default.
• W4288060877 startingPage "522" @default.
• W4288060877 abstract "To determine the association of pre-treatment neutrophil-to-lymphocyte ratio (NLR) with progression-free survival (PFS) and overall survival (OS) for patients with recurrent endometrial cancer (EC) treated with immunotherapy.Recurrent EC patients treated with immunotherapy alone or in combination from 2016 to 2021 were included. Demographics, pre-treatment laboratory results, pathologic data, response at first radiographic assessment, and cancer outcomes were obtained from the medical record. Kaplan-Meier curves were generated to compare PFS and OS stratified by NLR.The 106 patients included in the study were stratified by NLR <6 (n = 77, 72.6%) or NLR ≥6 (n = 29, 27.3%). Most had endometrioid pathology (59%), widely metastatic disease, and 36.8% had received ≥2 treatment lines before initiating immunotherapy. Mismatch repair deficiency (dMMR) was noted in 52 (49.1%) tumors. Most dMMR patients (94.3%) were treated with single-agent pembrolizumab, and most MMR proficient patients (78.7%) were treated with lenvatinb plus pembrolizumab. In the overall cohort, 40.2% (partial response (PR) 29.9%, complete response (CR) 10.4%) of patients with a NLR <6 responded at first radiographic assessment, compared to 31% (PR 27.5%, CR 3.4%) of patients with NLR ≥6 (p 0.691). Kaplan-Meier curves stratified by NLR <6 vs. ≥6 showed no difference in PFS. However, NLR <6 was associated with improved OS (p < 0.05). In the NLR < 6 group, the probability of survival at one year was 69% (95% CI: 58%, 82%), compared to 41% (95% CI: 26%, 67%) for the NLR > 6 group.Pre-treatment NLR <6 was associated with improved OS for recurrent EC patients treated with immunotherapy. NLR holds promise as a predictive biomarker for survival after immunotherapy treatment for patients with recurrent EC." @default.
• W4288060877 created "2022-07-28" @default.
• W4288060877 creator A5001596160 @default.
• W4288060877 creator A5034784898 @default.
• W4288060877 creator A5038146194 @default.
• W4288060877 creator A5039354231 @default.
• W4288060877 creator A5047088320 @default.
• W4288060877 creator A5050318574 @default.
• W4288060877 creator A5050406736 @default.
• W4288060877 creator A5050518250 @default.
• W4288060877 creator A5082512839 @default.
• W4288060877 date "2022-09-01" @default.
• W4288060877 modified "2023-10-16" @default.
• W4288060877 title "Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy" @default.
• W4288060877 cites W1873561454 @default.
• W4288060877 cites W1970614336 @default.
• W4288060877 cites W1971138161 @default.
• W4288060877 cites W1972640501 @default.
• W4288060877 cites W2033658212 @default.
• W4288060877 cites W2041901579 @default.
• W4288060877 cites W2043904711 @default.
• W4288060877 cites W2075691289 @default.
• W4288060877 cites W2088574179 @default.
• W4288060877 cites W2126592589 @default.
• W4288060877 cites W2150509444 @default.
• W4288060877 cites W2154516141 @default.
• W4288060877 cites W2157096396 @default.
• W4288060877 cites W2220762972 @default.
• W4288060877 cites W2325904644 @default.
• W4288060877 cites W2612419201 @default.
• W4288060877 cites W2622499649 @default.
• W4288060877 cites W2783295481 @default.
• W4288060877 cites W2801186408 @default.
• W4288060877 cites W2808419418 @default.
• W4288060877 cites W2883706035 @default.
• W4288060877 cites W2888378959 @default.
• W4288060877 cites W2895357007 @default.
• W4288060877 cites W2914335731 @default.
• W4288060877 cites W2940226797 @default.
• W4288060877 cites W2948132055 @default.
• W4288060877 cites W2977843586 @default.
• W4288060877 cites W2984359187 @default.
• W4288060877 cites W2991346563 @default.
• W4288060877 cites W2992331319 @default.
• W4288060877 cites W3011919019 @default.
• W4288060877 cites W3026767499 @default.
• W4288060877 cites W3030448313 @default.
• W4288060877 cites W3090741377 @default.
• W4288060877 cites W3100390287 @default.
• W4288060877 cites W3127371144 @default.
• W4288060877 cites W3158042384 @default.
• W4288060877 cites W3177367446 @default.
• W4288060877 cites W3210531242 @default.
• W4288060877 cites W4206041598 @default.
• W4288060877 cites W4206841660 @default.
• W4288060877 doi "https://doi.org/10.1016/j.ygyno.2022.07.010" @default.
• W4288060877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35907683" @default.
• W4288060877 hasPublicationYear "2022" @default.
• W4288060877 type Work @default.
• W4288060877 citedByCount "2" @default.
• W4288060877 countsByYear W42880608772023 @default.
• W4288060877 crossrefType "journal-article" @default.
• W4288060877 hasAuthorship W4288060877A5001596160 @default.
• W4288060877 hasAuthorship W4288060877A5034784898 @default.
• W4288060877 hasAuthorship W4288060877A5038146194 @default.
• W4288060877 hasAuthorship W4288060877A5039354231 @default.
• W4288060877 hasAuthorship W4288060877A5047088320 @default.
• W4288060877 hasAuthorship W4288060877A5050318574 @default.
• W4288060877 hasAuthorship W4288060877A5050406736 @default.
• W4288060877 hasAuthorship W4288060877A5050518250 @default.
• W4288060877 hasAuthorship W4288060877A5082512839 @default.
• W4288060877 hasConcept C10515644 @default.
• W4288060877 hasConcept C121608353 @default.
• W4288060877 hasConcept C126322002 @default.
• W4288060877 hasConcept C143998085 @default.
• W4288060877 hasConcept C2777088508 @default.
• W4288060877 hasConcept C2777701055 @default.
• W4288060877 hasConcept C2777761686 @default.
• W4288060877 hasConcept C2778963024 @default.
• W4288060877 hasConcept C2780057760 @default.
• W4288060877 hasConcept C2780739268 @default.
• W4288060877 hasConcept C3019894029 @default.
• W4288060877 hasConcept C71924100 @default.
• W4288060877 hasConcept C72563966 @default.
• W4288060877 hasConcept C90924648 @default.
• W4288060877 hasConceptScore W4288060877C10515644 @default.
• W4288060877 hasConceptScore W4288060877C121608353 @default.
• W4288060877 hasConceptScore W4288060877C126322002 @default.
• W4288060877 hasConceptScore W4288060877C143998085 @default.
• W4288060877 hasConceptScore W4288060877C2777088508 @default.
• W4288060877 hasConceptScore W4288060877C2777701055 @default.
• W4288060877 hasConceptScore W4288060877C2777761686 @default.
• W4288060877 hasConceptScore W4288060877C2778963024 @default.
• W4288060877 hasConceptScore W4288060877C2780057760 @default.
• W4288060877 hasConceptScore W4288060877C2780739268 @default.
• W4288060877 hasConceptScore W4288060877C3019894029 @default.
• W4288060877 hasConceptScore W4288060877C71924100 @default.
• W4288060877 hasConceptScore W4288060877C72563966 @default.

• next